Specialized Research

Argireline

Research Reagent · Laboratory Use Only

Quick Answer

How does Argireline reduce facial wrinkles in topical formulations?

Argireline (Acetyl Hexapeptide-3) is a synthetic peptide derived from SNAP-25 that interferes with SNARE complex assembly at facial neuromuscular junctions, reducing acetylcholine release and muscle contraction. Clinical studies of topical formulations report up to 30% wrinkle depth reduction at 28 days.

PMID12648022↗DOI10.1046/j.1467-2494.2002.00141.x↗⟳ Reconstitution Calculator
Scientific AbstractPMID 12648022 · 2002

Argireline (Acetyl Hexapeptide-3, sometimes Acetyl Hexapeptide-8) is a synthetic hexapeptide patterned on the N-terminal sequence of SNAP-25 that interferes with SNARE complex assembly at the neuromuscular junction. Topical application reduces acetylcholine release and muscle contraction in facial expression sites. Clinical studies demonstrate up to a 30% reduction in wrinkle depth after 28 days of twice-daily application in placebo-controlled formulations. The peptide is widely incorporated into cosmetic formulations marketed as topical alternatives to botulinum toxin.

Source:10.1046/j.1467-2494.2002.00141.x
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is Argireline?

Argireline (Acetyl Hexapeptide-3) is a topical anti-wrinkle peptide marketed as a non-invasive alternative to botulinum toxin injections.

Mechanism of Action

Argireline is a synthetic hexapeptide derived from SNAP-25 that competitively inhibits SNARE complex assembly, reducing acetylcholine release at facial neuromuscular junctions and decreasing muscle contraction at expression-line sites.

Observed Laboratory Results

  • Up to 30% wrinkle depth reduction in placebo-controlled cosmetic trials
  • Improvement at 28 days with twice-daily topical application
  • No systemic absorption with intact-skin application
  • Milder effect than injectable botulinum but with no needle requirement
Clinical Research ParametersHuman Study Registry

No registered clinical trials or indexed human study data currently available for Argireline via ClinicalTrials.gov or PubMed. This compound may be at preclinical or early research stages.

Search ClinicalTrials.gov ↗Search PubMed ↗
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. Argireline is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 12648022) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Specialized Research Research Compounds

DSIP
Although multi-modality neuroimages have advanced the early diagnosis of Alzheimer's Disea…
→
Kisspeptin-10
OBJECTIVES: The present study aimed to comprehensively elucidate how KP-10 modulates hormo…
→
Gonadorelin
PURPOSE: This study aimed to evaluate the pregnancy outcomes of frozen embryo transfer (FE…
→
Bremelanotide
OBJECTIVE: Sexual dysfunction is a common but underrecognized sequelae of breast and gynec…
→
View all Specialized Research compounds →